DK1332209T3 - Samlinger af repeatproteiner indeholdende repeatmoduler - Google Patents

Samlinger af repeatproteiner indeholdende repeatmoduler

Info

Publication number
DK1332209T3
DK1332209T3 DK01984591.6T DK01984591T DK1332209T3 DK 1332209 T3 DK1332209 T3 DK 1332209T3 DK 01984591 T DK01984591 T DK 01984591T DK 1332209 T3 DK1332209 T3 DK 1332209T3
Authority
DK
Denmark
Prior art keywords
repeat
collections
modules
proteins containing
repeat proteins
Prior art date
Application number
DK01984591.6T
Other languages
English (en)
Inventor
Michael Tobias Stumpp
Patrick Forrer
Hans Kaspar Binz
Andreas Plueckthun
Original Assignee
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Zuerich filed Critical Univ Zuerich
Application granted granted Critical
Publication of DK1332209T3 publication Critical patent/DK1332209T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK01984591.6T 2000-09-08 2001-09-10 Samlinger af repeatproteiner indeholdende repeatmoduler DK1332209T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00119670 2000-09-08
PCT/EP2001/010454 WO2002020565A2 (en) 2000-09-08 2001-09-10 Collections of repeat proteins comprising repeat modules

Publications (1)

Publication Number Publication Date
DK1332209T3 true DK1332209T3 (da) 2010-03-29

Family

ID=8169793

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01984591.6T DK1332209T3 (da) 2000-09-08 2001-09-10 Samlinger af repeatproteiner indeholdende repeatmoduler

Country Status (10)

Country Link
US (4) US7417130B2 (da)
EP (2) EP1332209B1 (da)
JP (3) JP5291279B2 (da)
AT (1) ATE448301T1 (da)
AU (1) AU2002218166A1 (da)
CA (1) CA2421447C (da)
DE (1) DE60140474D1 (da)
DK (1) DK1332209T3 (da)
ES (1) ES2335861T3 (da)
WO (1) WO2002020565A2 (da)

Families Citing this family (464)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US20060051861A1 (en) * 2004-09-07 2006-03-09 Clonex Development, Inc. Cell lines for use in increasing protein yield from a cell culture
US7875465B2 (en) 2005-05-31 2011-01-25 Canon Kabushiki Kaisha Target substance capturing molecule
US20070122413A1 (en) 2005-11-28 2007-05-31 Sivakumar Pallavur V Il-21 antagonists
AU2015203464B2 (en) * 2006-02-13 2017-08-10 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
AR059448A1 (es) * 2006-02-13 2008-04-09 Divergence Inc Polipeptidos quimericos vegetales de union para el reconocimiento molecular universal
AU2013201171B2 (en) * 2006-02-13 2016-01-21 Monsanto Technology Llc Plant chimeric binding polypeptides for universal molecular recognition
EP1996612A4 (en) 2006-03-03 2010-10-20 Univ Kingston COMPOSITIONS FOR THE TREATMENT OF CANCER
CA2650822C (en) 2006-04-28 2017-03-14 Esbatech Ag Antibodies binding to the extracellular domain of the receptor tyrosine kinase alk
CN101627055A (zh) 2006-09-05 2010-01-13 梅达雷克斯公司 骨形成蛋白及其受体的抗体以及它们的使用方法
SI2066351T1 (sl) 2006-10-02 2016-02-29 E.R. Squibb & Sons, L.L.C. Humana protitelesa, ki vežejo cxcr4 in njihova uporaba
JP5207222B2 (ja) * 2006-11-17 2013-06-12 独立行政法人農業生物資源研究所 ロイシンリッチリピート（ｌｒｒ）配列等反復配列を利用したタンパク質の作製方法
AU2007325838B2 (en) 2006-11-22 2013-09-19 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
SG177168A1 (en) 2006-12-01 2012-01-30 Medarex Inc Human antibodies that bind cd22 and uses thereof
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
US20100150950A1 (en) 2006-12-14 2010-06-17 Medarex, Inc. Human antibodies that bind cd70 and uses thereof
NZ579594A (en) 2007-03-12 2012-03-30 Esbatech Alcon Biomed Res Unit Sequence based engineering and optimization of single chain antibodies
US20100168016A1 (en) * 2007-04-11 2010-07-01 The Jackson Laboratory Diagnosis and treatment of diseases caused by misfolded proteins
EP2208737B1 (en) 2007-05-03 2017-07-05 Lysomab GmbH Complement factor H-derived short consensus repeat-antibody constructs
EP2155238B1 (en) 2007-06-05 2016-04-06 Yale University Antibody against d4 domain of the kit receptor and use thereor
CN101688200B (zh) 2007-06-25 2012-08-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 单链抗体的基于序列的改造和优化
NZ581468A (en) 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
TW200944231A (en) 2007-11-30 2009-11-01 Glaxo Group Ltd Antigen-binding constructs
EP2217268B1 (en) 2007-12-07 2016-05-04 ZymoGenetics, Inc. Anti-human il-21 monoclonal antibodies
WO2009100990A1 (en) * 2008-02-13 2009-08-20 Dsm Ip Assets B.V. Process for the production of a peptide
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
EP2263088A2 (en) * 2008-03-19 2010-12-22 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat protein module, rational design methods to create reagentless fluorescent biosensors and methods of their use
EP2103936A1 (en) * 2008-03-19 2009-09-23 Institut Pasteur Reagentless fluorescent biosensors comprising a designed ankyrin repeat module and methods of their design and use
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
PE20091964A1 (es) 2008-05-06 2010-01-09 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos
AR071874A1 (es) 2008-05-22 2010-07-21 Bristol Myers Squibb Co Proteinas de dominio de armazon basadas en fibronectina multivalentes
PL2307455T3 (pl) 2008-06-25 2017-09-29 Esbatech, An Alcon Biomedical Research Unit Llc Optymalizacja rozpuszczalności cząsteczek immunowiążących
KR20110036638A (ko) 2008-07-25 2011-04-07 리차드 더블유. 와그너 단백질 스크리닝 방법
US9433684B2 (en) 2008-08-19 2016-09-06 Nektar Therapeutics Conjugates of small-interfering nucleic acids
NZ592591A (en) * 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
TW201029662A (en) 2008-12-19 2010-08-16 Glaxo Group Ltd Novel antigen binding proteins
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
CA2753287A1 (en) 2009-02-24 2010-09-02 Glaxo Group Limited Antigen-binding constructs
EP2401296A1 (en) 2009-02-24 2012-01-04 Glaxo Group Limited Multivalent and/or multispecific rankl-binding constructs
US20110305693A1 (en) 2009-02-24 2011-12-15 Glaxo Group Limited Anitigen-binding constructs
CA2744103C (en) 2009-02-24 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Methods for identifying immunobinders of cell-surface antigens
JP5816558B2 (ja) 2009-03-05 2015-11-18 メダレックス・リミテッド・ライアビリティ・カンパニーＭｅｄａｒｅｘ， Ｌ．Ｌ．Ｃ． Ｃａｄｍ１に特異的な完全ヒト抗体
NZ616382A (en) 2009-04-20 2015-04-24 Oxford Biotherapeutics Ltd Antibodies specific to cadherin-17
IE20090514A1 (en) 2009-07-06 2011-02-16 Opsona Therapeutics Ltd Humanised antibodies and uses therof
EP2459053A2 (en) 2009-07-28 2012-06-06 F. Hoffmann-La Roche AG Non-invasive in vivo optical imaging method
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
TW201120210A (en) 2009-11-05 2011-06-16 Hoffmann La Roche Glycosylated repeat-motif-molecule conjugates
EP2496944A2 (en) 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
US20110150885A1 (en) 2009-12-11 2011-06-23 Atyr Pharma, Inc. Aminoacyl trna synthetases for modulating hematopoiesis
CA2787070A1 (en) 2010-01-28 2011-08-04 Ian Kirby Cd127 binding proteins
MX2012009318A (es) 2010-02-10 2012-09-07 Novartis Ag Metodos y compuestos para el crecimiento muscular.
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CA2797093C (en) 2010-04-26 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase
CA2797362C (en) 2010-04-27 2020-12-08 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl trna synthetases
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
EP2563383B1 (en) 2010-04-29 2017-03-01 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
US8986680B2 (en) 2010-04-29 2015-03-24 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
WO2011139986A2 (en) 2010-05-03 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-trna synthetases
CA2797977C (en) 2010-05-03 2019-08-20 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases
CN103140233B (zh) 2010-05-03 2017-04-05 Atyr 医药公司 与甲硫氨酰‑tRNA合成酶的蛋白片段相关的治疗、诊断和抗体组合物的发现
EP2566499B1 (en) 2010-05-04 2017-01-25 aTyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-trna synthetase complex
RU2012148816A (ru) 2010-05-07 2014-06-20 Ф. Хоффманн-Ля Рош Аг Метод диагностики для определения клеток ex vivo
EP3023496B1 (en) 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Compounds which modulate interleukins 17 and 23 signaling activity
CA2799197C (en) 2010-05-14 2019-10-29 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases
AU2011258106B2 (en) 2010-05-27 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
AR081556A1 (es) 2010-06-03 2012-10-03 Glaxo Group Ltd Proteinas de union al antigeno humanizadas
PT2591006T (pt) 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
JP6116479B2 (ja) 2010-07-12 2017-04-19 エータイアー ファーマ， インコーポレイテッド グリシルｔＲＮＡ合成酵素のタンパク質フラグメントに関連した治療用、診断用および抗体組成物の革新的発見
WO2012044992A2 (en) 2010-09-30 2012-04-05 Agency For Science, Technology And Research (A*Star) Methods and reagents for detection and treatment of esophageal metaplasia
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
MX351887B (es) 2010-11-23 2017-11-01 Glaxo Group Ltd Proteinas de union a antigeno para oncostatina m (osm).
MX2013005847A (es) 2010-11-24 2013-12-12 Glaxo Group Ltd Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
EP3514169B1 (en) * 2010-11-26 2024-03-06 Molecular Partners AG Designed repeat proteins binding to serum albumin
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US20140080153A1 (en) 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
US9499592B2 (en) * 2011-01-26 2016-11-22 President And Fellows Of Harvard College Transcription activator-like effectors
SI2675480T1 (sl) 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
EP2698431B1 (en) 2011-03-30 2020-09-09 Chugai Seiyaku Kabushiki Kaisha Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity
RU2623161C2 (ru) 2011-04-15 2017-06-22 Компуджен Лтд. Полипептиды и полинуклеотиды и их применение для лечения иммунологических нарушений и рака
WO2012149439A2 (en) * 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
SG10201500957QA (en) 2011-05-06 2015-04-29 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
AU2012252152B2 (en) 2011-05-06 2016-07-07 Zoetis Services Llc Anti-nerve growth factor antibodies and methods of preparing and using the same
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
PT3498732T (pt) 2011-05-06 2022-02-02 Zoetis Services Llc Anticorpos anti-fator de crescimento do nervo e método para preparação e utilização dos mesmos
EP2714737A1 (en) 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
CA2838833A1 (en) 2011-06-10 2012-12-13 Biogen Idec Ma Inc. Pro-coagulant compounds and methods of use thereof
RU2605595C2 (ru) 2011-06-13 2016-12-20 СиЭсЭл Лимитид Антитела против g-csfr и их применение
WO2012177837A2 (en) 2011-06-21 2012-12-27 Immunogen, Inc. Novel maytansinoid derivatives with peptide linker and conjugates thereof
EA031181B1 (ru) 2011-06-28 2018-11-30 Оксфорд Байотерепьютикс Лтд. Антитело, которое специфически связывается с bst1, или его антигенсвязывающий фрагмент, нуклеиновые кислоты, кодирующие его цепи, клетка-хозяин, способ получения этого антитела и применение для лечения рака и воспалительных заболеваний
US9447178B2 (en) 2011-06-28 2016-09-20 Oxford Biotherapeutics Ltd. Therapeutic and diagnostic target
WO2013002362A1 (ja) 2011-06-30 2013-01-03 中外製薬株式会社 ヘテロ二量化ポリペプチド
KR102366029B1 (ko) 2011-09-30 2022-02-23 추가이 세이야쿠 가부시키가이샤 표적 항원에 대한 면역응답을 유도하는 항원 결합 분자
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
CN107287660A (zh) 2011-09-30 2017-10-24 中外制药株式会社 离子浓度依赖性结合分子文库
KR20250078601A (ko) 2011-09-30 2025-06-02 추가이 세이야쿠 가부시키가이샤 항원의 소실을 촉진시키는 항원 결합 분자
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP2765192A4 (en) 2011-10-05 2015-04-15 Chugai Pharmaceutical Co Ltd ANTIGENBINDING MOLECULE FOR PREPARING A SPACE BETWEEN A PLASMA AND AN ANTIGEN WITH A SACCHARIDE CHAIN RECEPTOR BINDING DOMAIN
JP2015504413A (ja) 2011-10-28 2015-02-12 パトリス リミテッド Ｐａｔ−ｌｍ１エピトープおよびそれを使用するための方法
US20130156766A1 (en) 2011-11-15 2013-06-20 Allergan, Inc. Treatment of dry age related macular degeneration
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP2612916A1 (en) 2012-01-09 2013-07-10 Universität Zürich Cellular high throughput encapsulation for screening or selection
CN104159922B (zh) 2012-01-10 2018-03-02 比奥根Ma公司 对转运治疗性分子穿过血脑屏障的增强
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
SG10201708562VA (en) 2012-02-13 2017-12-28 Agency Science Tech & Res IL-1β Neutralizing Human Monoclonal Antibodies
EP2814514B1 (en) 2012-02-16 2017-09-13 Atyr Pharma, Inc. Histidyl-trna synthetases for treating autoimmune and inflammatory diseases
WO2013121038A1 (en) 2012-02-17 2013-08-22 Centro Nacional De Investigaciones Oncológicas Mammalian homologues of flower, their use in cancer diagnostics, prevention and treatment
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
WO2013180200A1 (ja) 2012-05-30 2013-12-05 中外製薬株式会社 標的組織特異的抗原結合分子
JPWO2013180201A1 (ja) 2012-05-30 2016-01-21 中外製薬株式会社 会合化した抗原を消失させる抗原結合分子
EP4310191A3 (en) 2012-06-14 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule containing modified fc region
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
SG11201408196RA (en) * 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
AR091774A1 (es) * 2012-07-16 2015-02-25 Dow Agrosciences Llc Proceso para el diseño de las secuencias de adn repetidas, largas, divergentes de codones optimizados
EP2692731A1 (en) * 2012-07-31 2014-02-05 Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe Recombinant Adeno-Associated virus (AAV) vector particles displaying high-affinity ligands for cell-type specific gene delivery
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
HK1211208A1 (zh) 2012-08-22 2016-05-20 Immunogen, Inc. 細胞毒性苯並二氮呯衍生物
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスＦｃγＲＩＩ特異的Ｆｃ抗体
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
BR112015006634B1 (pt) 2012-09-28 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Método e kit para avaliação de reação de coagulação sanguínea
EP2906591A1 (en) 2012-10-15 2015-08-19 Universität Zürich Bispecific her2 ligands for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
CN104755500B (zh) 2012-11-08 2020-10-02 霍夫曼-拉罗奇有限公司 结合HER3 β-发夹的HER3抗原结合蛋白
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
KR20150095684A (ko) 2012-12-18 2015-08-21 노파르티스 아게 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법
CN105102618B (zh) 2012-12-27 2018-04-17 中外制药株式会社 异源二聚化多肽
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
JP6416793B2 (ja) 2013-02-28 2018-10-31 カプリオン プロテオミクス インコーポレーテッド 結核のバイオマーカー及びその使用
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
SG11201505926VA (en) 2013-03-15 2015-09-29 Biogen Ma Inc Factor ix polypeptide formulations
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
KR102236367B1 (ko) 2013-07-26 2021-04-05 삼성전자주식회사 DARPin을 포함하는 이중 특이 키메라 단백질
CA2926215A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modified pseudomonas exotoxin a
EP3628324A1 (en) 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
WO2015070014A1 (en) 2013-11-08 2015-05-14 Biogen Idec Ma Inc. Procoagulant fusion compound
TWI702316B (zh) 2013-12-04 2020-08-21 日商中外製藥股份有限公司 因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
CN105979965B (zh) 2013-12-18 2021-07-09 杰特有限公司 治疗伤口的方法
US10273301B2 (en) 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
KR20150092638A (ko) 2014-02-05 2015-08-13 삼성전자주식회사 p15 단백질 변이체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR20150092637A (ko) 2014-02-05 2015-08-13 삼성전자주식회사 p16 단백질 변이체 및 이를 포함하는 암의 예방 또는 치료용 조성물
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
TW201625299A (zh) 2014-06-20 2016-07-16 Chugai Pharmaceutical Co Ltd 用於因第ｖｉｉｉ凝血因子及／或活化的第ｖｉｉｉ凝血因子的活性降低或欠缺而發病及／或進展的疾病之預防及／或治療之醫藥組成物
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
US20170327553A1 (en) 2014-06-25 2017-11-16 Novartis Ag Compositions and methods for long acting proteins
CN106661578B (zh) 2014-08-15 2020-08-04 埃迪恩克斯股份有限公司 用于疼痛治疗的寡核苷酸诱饵
EP3189057A1 (en) 2014-09-03 2017-07-12 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
CR20170111A (es) 2014-09-03 2017-05-23 Immunogen Inc Derivados de benzodiazepina citotóxicos
RU2715905C2 (ru) 2014-10-01 2020-03-04 МЕДИММЬЮН, ЭлЭлСи Способ конъюгации полипептида
WO2016059602A2 (en) 2014-10-16 2016-04-21 Glaxo Group Limited Methods of treating cancer and related compositions
ES2788979T3 (es) 2014-11-14 2020-10-23 Hoffmann La Roche Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia de TNF
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
JP6743022B2 (ja) 2014-12-24 2020-08-19 ネクシミューン インコーポレイテッド 免疫療法のためのナノ粒子組成物及び方法
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
US9458211B1 (en) 2015-04-02 2016-10-04 Molecular Partners Ag Recombinant proteins that simultaneously bind HGF, VEGF-A and serum albumin, comprising ankyrin repeat domains
FI3284480T3 (fi) 2015-04-14 2025-09-11 Chugai Pharmaceutical Co Ltd IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi
CA2978038A1 (en) 2015-04-17 2016-10-20 F. Hoffmann-La Roche Ag Combination therapy with coagulation factors and multispecific antibodies
WO2016193497A1 (en) 2015-06-04 2016-12-08 Ospedale San Raffaele Srl Inhibitor of igfbp3/tmem219 axis and diabetes
CA2986080C (en) 2015-06-04 2023-12-05 Ospedale San Raffaele Srl Inhibitor of igfbp3 for the treatment of intestinal disorders
KR101713944B1 (ko) 2015-06-19 2017-03-09 한국과학기술원 신규한 혈관내피세포 성장인자와 결합할 수 있는 폴리펩타이드 및 이의 용도
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
CA2992797A1 (en) 2015-08-03 2017-02-09 Engmab Sarl Monoclonal antibodies against bcma
PE20181336A1 (es) 2015-09-18 2018-08-21 Chugai Pharmaceutical Co Ltd Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
EP3356405B1 (en) 2015-10-02 2026-07-08 F. Hoffmann-La Roche AG Anti-human cd19 antibodies with high affinity
MA43028B1 (fr) 2015-10-02 2021-09-30 Hoffmann La Roche Anticorps bispécifiques pour pd1 et tim3
MY206406A (en) 2015-10-02 2024-12-16 Hoffmann La Roche Bispecific antibodies specific for a costimulatory tnf receptor
PE20181349A1 (es) 2015-10-07 2018-08-22 Hoffmann La Roche Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
EP3371311B1 (en) 2015-11-06 2021-07-21 Orionis Biosciences BV Bi-functional chimeric proteins and uses thereof
EP3377080B1 (en) 2015-11-19 2024-02-14 Asclepix Therapeutics, LLC Peptides with anti-angiogenic, anti-lymphangiogenic, and anti-edemic properties and nanoparticle formulations
AU2016361462B2 (en) 2015-11-27 2023-09-21 Csl Limited CD131 binding proteins and uses thereof
US10597466B2 (en) 2015-12-02 2020-03-24 Fred Hutchinson Cancer Research Center Circular tandem repeat proteins
EA201891420A1 (ru) 2015-12-18 2019-02-28 Чугаи Сейяку Кабусики Кайся Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
CN109071632B (zh) 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
US11248057B2 (en) 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
EP3231813A1 (en) 2016-03-29 2017-10-18 F. Hoffmann-La Roche AG Trimeric costimulatory tnf family ligand-containing antigen binding molecules
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
EP3243836A1 (en) 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG C-terminally fused tnf family ligand trimer-containing antigen binding molecules
EP3455254B1 (en) 2016-05-11 2021-07-07 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety
WO2017194783A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Targeted mutant interferon-beta and uses thereof
EP3455245A2 (en) 2016-05-13 2019-03-20 Orionis Biosciences NV Therapeutic targeting of non-cellular structures
EP3243832A1 (en) 2016-05-13 2017-11-15 F. Hoffmann-La Roche AG Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
TWI760396B (zh) 2016-06-17 2022-04-11 日商中外製藥股份有限公司 抗肌抑素抗體及使用方法
WO2018011405A1 (en) 2016-07-15 2018-01-18 Universität Zürich Il-13ralpha1 antibodies for use in treatment of atopic inflammation, sepsis and neutropenia
US11352438B2 (en) 2016-09-06 2022-06-07 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
JP2020501508A (ja) 2016-09-15 2020-01-23 クアドルセプト バイオ リミテッド 多量体、四量体および八量体
MY196882A (en) 2016-09-22 2023-05-08 Molecular Partners Ag Recombinant binding proteins and their use
CA3034105A1 (en) 2016-09-23 2018-03-29 Csl Limited Coagulation factor binding proteins and uses thereof
WO2018067646A1 (en) 2016-10-04 2018-04-12 Asclepix Therapeutics, Llc Compounds and methods for activating tie2 signaling
CN110114368B (zh) 2016-10-24 2024-08-02 奥睿尼斯生物科学私人有限公司 靶向突变干扰素-γ及其用途
US11124577B2 (en) 2016-11-02 2021-09-21 Engmab Sàrl Bispecific antibody against BCMA and CD3 and an immunological drug for combined use in treating multiple myeloma
CA3036983A1 (en) 2016-11-21 2018-05-24 Cureab Gmbh Anti-gp73 antibodies and immunoconjugates
CA3041279A1 (en) 2016-11-28 2018-05-31 Chugai Seiyaku Kabushiki Kaisha Antigen-binding domain, and polypeptide including conveying section
AU2017364818C1 (en) 2016-11-28 2025-05-15 Chugai Seiyaku Kabushiki Kaisha Ligand-binding molecule having adjustable ligand binding activity
JP7125400B2 (ja) 2016-12-19 2022-08-24 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 標的化４－１ｂｂ（ｃｄ１３７）アゴニストとの併用療法
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CA3047070A1 (en) 2017-01-03 2018-07-12 F.Hoffmann-La Roche Ag Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
EP3576765B1 (en) 2017-02-06 2025-07-16 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CA3050601A1 (en) 2017-02-07 2018-08-16 Vib Vzm Immune-cell targeted bispecific chimeric proteins and uses thereof
IL298414B2 (en) 2017-02-28 2024-12-01 Immunogen Inc Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
WO2018178076A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178055A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Bispecific antigen binding molecule for a costimulatory tnf receptor
WO2018178074A1 (en) 2017-03-29 2018-10-04 F. Hoffmann-La Roche Ag Trimeric antigen binding molecules specific for a costimulatory tnf receptor
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
CN110402255B (zh) 2017-04-04 2022-12-02 豪夫迈·罗氏有限公司 新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
WO2018195243A1 (en) 2017-04-20 2018-10-25 Immunogen, Inc. Cytotoxic benzodiazepine derivatives and conjugates thereof
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
US11674959B2 (en) 2017-08-03 2023-06-13 The Johns Hopkins University Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
KR102755742B1 (ko) 2017-09-11 2025-01-15 모나쉬 유니버시티 인간 트롬빈 수용체 par4 결합 단백질
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said moleculeas active ingredient
WO2019075056A1 (en) 2017-10-10 2019-04-18 The Johns Hopkins University BIODEGRADABLE BIOMIMETIC PARTICLES
KR102715492B1 (ko) 2017-10-18 2024-10-11 씨에스엘 리미티드 인간 혈청 알부민 변이체 및 이의 용도
EP3704155A2 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Combination therapy with targeted ox40 agonists
PE20210844A1 (es) 2017-11-01 2021-05-10 Hoffmann La Roche Contorsbodies 2 + biespecificos
CN111246884A (zh) 2017-11-01 2020-06-05 豪夫迈·罗氏有限公司 新颖的含有tnf家族配体三聚体的抗原结合分子
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
KR20250134208A (ko) 2017-11-28 2025-09-09 추가이 세이야쿠 가부시키가이샤 항원 결합 도메인 및 운반 부분을 포함하는 폴리펩티드
US20210179721A1 (en) 2017-11-29 2021-06-17 Csl Limited Method of treating or preventing ischemia-reperfusion injury
EP3502140A1 (en) 2017-12-21 2019-06-26 F. Hoffmann-La Roche AG Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
WO2019133652A1 (en) 2017-12-28 2019-07-04 Immunogen, Inc. Benzodiazepine derivatives
US11466077B2 (en) 2018-01-05 2022-10-11 Ac Immune Sa Misfolded TDP-43 binding molecules
US12655186B2 (en) 2018-01-26 2026-06-16 Orionis Biosciences, Inc. Chimeric protein comprising anti-XCR1 antibody and modified interferon alpha 2
JP2021511782A (ja) 2018-01-31 2021-05-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 安定化された免疫グロブリンドメイン
JP2021511793A (ja) 2018-01-31 2021-05-13 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｌａｇ３に結合する抗原結合部位を含む二重特異性抗体
CA3090406A1 (en) 2018-02-05 2019-08-08 Orionis Biosciences, Inc. Fibroblast binding agents and use thereof
CA3091646A1 (en) 2018-02-14 2019-08-22 Abba Therapeutics Ag Anti-human pd-l2 antibodies
US20210032352A1 (en) 2018-02-14 2021-02-04 Antera Therapeutics Inc. Multivalent Binding Molecules Activating WNT Signaling and Uses Thereof
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
TWI841551B (zh) 2018-03-13 2024-05-11 瑞士商赫孚孟拉羅股份公司 使用靶向4-1bb (cd137)之促效劑的組合療法
PL3765489T3 (pl) 2018-03-13 2025-02-10 F. Hoffmann-La Roche Ag Terapeutyczne połączenie agonistów 4-1BB z przeciwciałami anty-CD20
GB201804092D0 (en) * 2018-03-14 2018-04-25 Imperial Innovations Ltd Methods and compositions
CA3094176A1 (en) 2018-03-22 2019-09-26 Charite-Universitatsmedizin Berlin Crispr associated protein reactive t cell immunity
US12281160B2 (en) 2018-03-23 2025-04-22 Csl Limited Method of treating asthma
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CR20200459A (es) 2018-04-13 2020-11-11 Hoffmann La Roche Moléculas de unión a antígeno dirigidas a her2 que comprendan 4-1bbl
WO2019204643A2 (en) * 2018-04-18 2019-10-24 Altius Institute For Biomedical Sciences Animal pathogen-derived polypeptides and uses thereof for genetic engineering
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
WO2019238966A1 (en) 2018-06-15 2019-12-19 Universität Bern LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES
WO2019244973A1 (ja) 2018-06-20 2019-12-26 中外製薬株式会社 標的細胞に対する免疫反応を活性化する方法およびその組成物
WO2020006126A1 (en) 2018-06-27 2020-01-02 Altius Institute For Biomedical Sciences Nucleic acid binding domains and methods of use thereof
TW202035447A (zh) 2018-07-04 2020-10-01 瑞士商赫孚孟拉羅股份公司 新穎雙特異性促效性4-1bb抗原結合分子
MX2021001431A (es) 2018-08-10 2021-05-12 Chugai Pharmaceutical Co Ltd Molecula de union al antigeno anti grupo de diferenciacion 137 (cd137) y su uso.
CN112654641A (zh) 2018-10-01 2021-04-13 豪夫迈·罗氏有限公司 具有与cd40的三价结合的双特异性抗原结合分子
US11242396B2 (en) 2018-10-01 2022-02-08 Hoffmann-La Roche Inc. Bispecific antigen binding molecules comprising anti-FAP clone 212
EP3632929A1 (en) 2018-10-02 2020-04-08 Ospedale San Raffaele S.r.l. Antibodies and uses thereof
KR20210075080A (ko) 2018-10-08 2021-06-22 유니베르시태트 취리히 Her2-결합 사량체 폴리펩티드
WO2020089437A1 (en) 2018-10-31 2020-05-07 Engmab Sàrl Combination therapy
EP3890773A4 (en) 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
WO2020104627A1 (en) 2018-11-21 2020-05-28 Universität Zürich Photochemically induced conjugation of radiometals to small molecules, peptides and nanoparticles in a simultaneous one-pot reaction
KR20210099614A (ko) 2018-12-04 2021-08-12 노파르티스 아게 Cd3에 대한 결합 분자 및 이의 용도
CR20210326A (es) 2018-12-21 2021-09-10 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
US20200223925A1 (en) 2018-12-21 2020-07-16 Hoffmann-La Roche Inc. Tumor-targeted superagonistic cd28 antigen binding molecules
EP3677911A3 (en) 2019-01-03 2020-07-29 Universität Basel Use of non-agonist ligands for suppression of metastasis
WO2020144378A1 (en) 2019-01-11 2020-07-16 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia after bariatric surgery
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
CN119708241A (zh) 2019-02-15 2025-03-28 因特格尔莫来库乐有限公司 密封蛋白6抗体及其用途
WO2020175502A1 (ja) 2019-02-27 2020-09-03 国立大学法人東京医科歯科大学 抗原結合タンパク質と蛍光タンパク質または蛍光標識されるタグタンパク質との融合タンパク質
GB201903233D0 (en) 2019-03-08 2019-04-24 Oxford Genetics Ltd Method of selecting for antibodies
US20220154174A1 (en) 2019-03-08 2022-05-19 Oxford Genetics Limited Method of Selecting for Antibodies
GB201903767D0 (en) 2019-03-19 2019-05-01 Quadrucept Bio Ltd Multimers, tetramers & octamers
JP7601758B2 (ja) 2019-03-19 2024-12-17 中外製薬株式会社 Ｍｔａ依存的に抗原に対する結合活性が変化する抗原結合ドメインを含む抗原結合分子及び当該抗原結合ドメイン取得用ライブラリ
AU2020240310A1 (en) 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
WO2020198665A1 (en) 2019-03-28 2020-10-01 Orionis Biosciences, Inc. Fibroblast activation protein binding agents and use thereof
US20230094471A1 (en) 2019-03-29 2023-03-30 Immunogen, Inc. Cytotoxic bis-benzodiazepine derivatives and conjugates thereof with cell-binding agents for inhibiting abnormal cell growth or for treating proliferative diseases
SG11202110076PA (en) 2019-04-02 2021-10-28 Chugai Pharmaceutical Co Ltd Method of introducing target-specific foreign gene
EP3953712A1 (en) 2019-04-10 2022-02-16 Universität Zürich A method for determining the likelihood of a patient being responsive to cancer immunotherapy
CN113677403B (zh) 2019-04-12 2024-12-27 豪夫迈·罗氏有限公司 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
CA3133909A1 (en) 2019-04-18 2020-10-22 Elpida TSIKA Novel molecules for therapy and diagnosis
RS64961B1 (sr) 2019-04-26 2024-01-31 Immunogen Inc Derivati kamptotecina
US12037378B2 (en) 2019-05-21 2024-07-16 Novartis Ag Variant CD58 domains and uses thereof
AU2020279224B2 (en) 2019-05-21 2024-12-05 Novartis Ag Trispecific binding molecules against BCMA and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN114008073B (zh) 2019-05-23 2025-08-12 Ac免疫有限公司 抗tdp-43结合分子及其用途
CA3139164A1 (en) 2019-06-04 2020-12-10 Molecular Partners Ag Recombinant fap binding proteins and their use
EP3980452A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
JP2022535564A (ja) 2019-06-04 2022-08-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 多選択性タンパク質
KR20220016944A (ko) 2019-06-04 2022-02-10 몰리큘라 파트너스 아게 개선된 안정성을 갖는 설계된 안키린 반복 도메인
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN113905757B (zh) 2019-06-05 2026-01-13 中外制药株式会社 抗体切割位点结合分子
WO2020246617A1 (ja) 2019-06-07 2020-12-10 中外製薬株式会社 情報処理システム、情報処理方法、プログラム、及び、抗原結合分子或いはタンパク質を製造する方法
WO2020254540A1 (en) 2019-06-18 2020-12-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Site-specific, kinetically inert conjugation of labels and/or carriers to target molecules such as his-tagged proteins via metal complex reagents
BR112021026293A2 (pt) 2019-06-26 2022-03-03 Hoffmann La Roche Moléculas de ligação, anticorpos humanizados, ácido nucleico isolado, célula hospedeira, métodos para produzir a molécula de ligação ao antígeno, para tratar um indivíduo e suprarregular ou prolongar a atividade de células t citotóxicas, composição farmacêutica e uso da molécula
EP3990492A1 (en) 2019-06-27 2022-05-04 F. Hoffmann-La Roche AG Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
EP4025693A1 (en) 2019-09-05 2022-07-13 Genome Biologics UG Inhibition of mthfd1l for use in hypertrophic heart disease and heart failure
CN116478292A (zh) 2019-11-15 2023-07-25 恩瑟拉有限责任公司 Tmem219抗体及其治疗性用途
CA3161178A1 (en) 2019-11-20 2021-05-27 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Archaeal peptide recombinase - a novel peptide ligating enzyme
WO2021100794A1 (ja) 2019-11-20 2021-05-27 中外製薬株式会社 抗体含有製剤
EP4061839A1 (en) 2019-11-21 2022-09-28 Enthera S.R.L. Igfbp3 antibodies and therapeutic uses thereof
US20230000918A1 (en) 2019-11-29 2023-01-05 Suzhou Nova Therapeutics Co. Ltd Chimeric antigen receptors, compositions and applications thereof
AU2020402581A1 (en) 2019-12-11 2022-06-23 Molecular Partners Ag Designed ankyrin repeat domains with altered surface residues
CN114945584A (zh) 2019-12-11 2022-08-26 分子合作伙伴股份公司 重组肽-mhc复合物结合蛋白及其生成和用途
WO2021122813A1 (en) 2019-12-16 2021-06-24 Universität Basel Angiogenesis promoting agents for prevention of metastatic cancer
IL295382B1 (en) 2020-02-12 2026-08-01 Chugai Seiyaku Kk Anti-CD137 antigen-binding molecule for use in cancer treatment
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
WO2021176008A1 (en) 2020-03-04 2021-09-10 Cornell University Agents targeting baf155 or brg1 for use in treatment of advanced prostate cancer
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
WO2021195513A1 (en) 2020-03-27 2021-09-30 Novartis Ag Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
GB202004514D0 (en) 2020-03-27 2020-05-13 Inst De Medicina Molecular Joaeo Lobo Antunes Treatment of Immunosuppressive Cancer
AR121706A1 (es) 2020-04-01 2022-06-29 Hoffmann La Roche Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
EP4132578A1 (en) 2020-04-06 2023-02-15 Universität Zürich Artc1 ligands for cancer treatment
MX2022013945A (es) 2020-05-06 2023-02-14 Molecular Partners Ag Nuevas proteinas de union a repeticiones de anquirina y sus usos.
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
AU2021271131A1 (en) 2020-05-14 2022-12-15 Molecular Partners Ag Recombinant CD40 binding proteins and their use
JP2023504675A (ja) 2020-05-19 2023-02-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ガンの処置のための結合分子
WO2021239844A1 (en) 2020-05-27 2021-12-02 Universitätsspital Basel Sglt-2 inhibitors or il-1r antagonists for reduction of hypoglycaemia in prediabetes
WO2021239999A1 (en) 2020-05-28 2021-12-02 Universität Zürich Il-12 pd-l1 ligand fusion protein
CN115768475A (zh) 2020-06-04 2023-03-07 Csl创新私人有限公司 治疗或预防急性呼吸窘迫综合征的方法
CR20220627A (es) 2020-06-23 2023-02-17 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se derigen a her2
CN115916830A (zh) 2020-06-25 2023-04-04 豪夫迈·罗氏有限公司 抗cd3/抗cd28双特异性抗原结合分子
TW202220677A (zh) 2020-07-31 2022-06-01 日商中外製藥股份有限公司 含有表現嵌合受體之細胞的醫藥組成物
CN116033921A (zh) 2020-08-07 2023-04-28 豪夫迈·罗氏有限公司 用于生产蛋白质组合物的方法
CN116615452A (zh) 2020-08-14 2023-08-18 Ac免疫有限公司 人源化抗tdp-43结合分子及其用途
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
US12692306B2 (en) 2020-08-18 2026-07-28 Universität Zürich CD25-biased anti-IL-2 antibody
EP4204448A2 (en) 2020-08-27 2023-07-05 cureab GmbH Anti-golph2 antibodies for macrophage and dendritic cell differentiation
CA3189847A1 (en) 2020-09-01 2022-03-10 Naoki Fukazawa Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient
CA3195512A1 (en) 2020-10-14 2022-04-21 Vahe Bedian Compositions and methods for treatment of thyroid eye disease
TW202228789A (zh) 2020-10-15 2022-08-01 美商建南德克公司 用於長效遞送治療劑之多能蛋白聚醣（ｖｇ１）的玻尿酸結合衍生物
WO2022079297A1 (en) 2020-10-16 2022-04-21 Ac Immune Sa Antibodies binding to alpha-synuclein for therapy and diagnosis
CN112230587B (zh) * 2020-10-29 2021-08-10 中国民用航空总局第二研究所 一种仪表着陆系统同频异呼运行监测系统及方法
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
WO2022101458A1 (en) 2020-11-16 2022-05-19 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted cd40 agonists
US20240018265A1 (en) 2020-12-11 2024-01-18 Friedrich Miescher Institute For Biomedical Research Hdac6 binding proteins and their anti-viral use
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
US20240108746A1 (en) 2020-12-16 2024-04-04 Molecular Partners Ag Novel slow-release prodrugs
CN116829598A (zh) 2021-01-06 2023-09-29 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和cd20 t细胞双特异性抗体的组合疗法
AU2022218137A1 (en) 2021-02-03 2023-08-24 Mozart Therapeutics, Inc. Binding agents and methods of using the same
US20240310378A1 (en) 2021-02-11 2024-09-19 Universität Zürich Use of markers found on lymph node metastatic samples for the prognosis of breast cancer
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
WO2022190016A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
WO2022243261A1 (en) 2021-05-19 2022-11-24 F. Hoffmann-La Roche Ag Agonistic cd40 antigen binding molecules targeting cea
EP4342984A4 (en) 2021-05-19 2025-04-23 Chugai Seiyaku Kabushiki Kaisha Method for predicting in vivo pharmacokinetics of molecule
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
KR20240028452A (ko) 2021-07-02 2024-03-05 제넨테크, 인크. 암을 치료하기 위한 방법 및 조성물
IL310612A (en) 2021-08-05 2024-04-01 Immunos Therapeutics Ag HLA-B57 is different with increased expression levels
MX2024001691A (es) 2021-08-05 2024-04-19 Immunos Therapeutics Ag Medicamentos de combinación que comprenden proteínas de fusión de antígeno leucocitario de humano (hla).
JP2024531151A (ja) 2021-08-10 2024-08-29 ビリジアン セラピューティクス， インコーポレイテッド 甲状腺眼疾患の処置のための組成物、用量および方法
WO2023021006A1 (en) 2021-08-16 2023-02-23 Universität Zürich Il-1 targeting agents for treatment of pitiyriasis rubra pilaris
EP4137508A1 (en) 2021-08-17 2023-02-22 Athebio AG Variants of ankyrin repeat domains
WO2023021050A1 (en) 2021-08-17 2023-02-23 Athebio Ag Variants of ankyrin repeat domains
JP2024532620A (ja) 2021-08-30 2024-09-05 ラッセン・セラピューティクス１・インコーポレイテッド 抗ＩＬ－１１Ｒα抗体
WO2023036849A1 (en) 2021-09-07 2023-03-16 ETH Zürich Identifying and predicting future coronavirus variants
EP4163380A1 (en) 2021-10-08 2023-04-12 ETH Zurich Device and method for manipulation of extracellular vesicles
WO2023076876A1 (en) 2021-10-26 2023-05-04 Mozart Therapeutics, Inc. Modulation of immune responses to viral vectors
EP4433167A1 (en) 2021-11-16 2024-09-25 AC Immune SA Novel molecules for therapy and diagnosis
WO2023110983A1 (en) 2021-12-14 2023-06-22 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
WO2023110942A1 (en) 2021-12-14 2023-06-22 Charité-Universitätsmedizin Berlin Prevention of impaired fracture healing
CR20240246A (es) 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250382633A1 (en) 2021-12-21 2025-12-18 Universität Zürich Adenoviral vectors
AU2023221539A1 (en) 2022-02-16 2024-08-22 Ac Immune Sa Humanized anti-tdp-43 binding molecules and uses thereof
WO2023180527A1 (en) 2022-03-25 2023-09-28 Universität Zürich Adenoviral mediated targeting of activated immune cells
EP4499229A1 (en) 2022-03-28 2025-02-05 F. Hoffmann-La Roche AG Interferon gamma variants and antigen binding molecules comprising these
JPWO2023195515A1 (da) * 2022-04-06 2023-10-12
IL316153A (en) 2022-04-08 2024-12-01 Ac Immune Sa Anti-tdp-43 binding molecules
EP4260907A1 (en) 2022-04-11 2023-10-18 Universität Zürich Agents for treatment of endometriosis and other benign gynecological neoplasms
JP2025517657A (ja) 2022-05-10 2025-06-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル シンシチン－１融合タンパク質及び標的細胞へのカーゴ送達のためのその使用
WO2024002914A1 (en) 2022-06-27 2024-01-04 Charité-Universitätsmedizin Berlin Prediction of, and composition to improve, tendon healing
US20250304677A1 (en) 2022-07-04 2025-10-02 Vib Vzw Blood-Cerebrospinal Fluid Barrier Crossing Antibodies
CA3262553A1 (en) * 2022-08-01 2024-02-08 Molecular Partners Ag REHEARSAL AREAS DESIGNED WITH MODIFIED CHARGES AND THEIR USE
WO2024030956A2 (en) 2022-08-03 2024-02-08 Mozart Therapeutics, Inc. Cd39-specific binding agents and methods of using the same
WO2024037743A1 (en) 2022-08-16 2024-02-22 Athebio Ag Variants of ankyrin repeat domains
EP4573106A2 (en) 2022-08-16 2025-06-25 Athebio AG Variants of ankyrin repeat domains
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
WO2024044770A1 (en) 2022-08-26 2024-02-29 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer
EP4581055A1 (en) 2022-08-31 2025-07-09 Universität Zürich Adenoviral-based in situ delivery of bispecific t cell engagers
EP4587122A1 (en) 2022-09-15 2025-07-23 Avidicure IP B.V. Multispecific antigen binding proteins for stimulating nk cells and use thereof
AU2023356326A1 (en) 2022-10-06 2025-03-27 Bicara Therapeutics Inc. Multispecific proteins and related methods
EP4598945A1 (en) 2022-10-07 2025-08-13 Universität Zürich Paracrine adenoviral delivery of biomolecules
WO2024094741A1 (en) 2022-11-03 2024-05-10 F. Hoffmann-La Roche Ag Combination therapy with anti-cd19/anti-cd28 bispecific antibody
GB202216503D0 (en) 2022-11-05 2022-12-21 Quadrucept Bio Ltd Non-human vertebrates & cells
CN120282987A (zh) 2022-11-30 2025-07-08 因特格尔莫来库乐有限公司 包括双特异性型式的针对紧密连接蛋白6的抗体
EP4638473A1 (en) 2022-12-19 2025-10-29 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Means and methods to target endogenous condensates
EP4646433A1 (en) 2023-01-06 2025-11-12 Lassen Therapeutics, Inc. Anti-il-18bp antibodies
TW202430560A (zh) 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
JP2026514293A (ja) 2023-02-08 2026-05-08 イムノス セラピューティクス アーゲー β２ミクログロブリン、ＨＬＡ重鎖ポリペプチド及びＣＤ４７－ＳＩＲＰαの阻害剤の融合タンパク質
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2024184494A1 (en) 2023-03-08 2024-09-12 Ac Immune Sa Anti-tdp-43 binding molecules and uses thereof
EP4428159A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Melanoma targeting human antibodies and therapeutic uses thereof
EP4428158A1 (en) 2023-03-10 2024-09-11 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Lung cancer targeting human antibodies and therapeutic uses thereof
CN120835901A (zh) 2023-03-13 2025-10-24 豪夫迈·罗氏有限公司 采用pd1-lag3双特异性抗体和hla-g t细胞双特异性抗体的组合疗法
JP2026519919A (ja) 2023-04-03 2026-06-19 ブイアイビー ブイゼットダブリュ 血液脳関門通過抗体
EP4720124A1 (en) 2023-05-24 2026-04-08 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same
EP4720121A1 (en) 2023-06-01 2026-04-08 F. Hoffmann-La Roche AG Immunostimulatory antigen binding molecules that specifically bind to bcma
TW202504918A (zh) 2023-06-01 2025-02-01 瑞士商赫孚孟拉羅股份公司 靶向ｂｃｍａ及ｃｄ２８的雙特異性抗體
JP2026524079A (ja) 2023-06-06 2026-07-17 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｃｄ２結合タンパク質及びその使用
EP4724473A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd47 binding proteins and their use
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2024261027A1 (en) 2023-06-19 2024-12-26 Vector Biopharma Ag Il-7-retargeting of adenoviruses for cell specific infection
WO2024261013A1 (en) 2023-06-21 2024-12-26 F. Hoffmann-La Roche Ag Combination therapy with fap-targeted lymphotoxin beta receptor agonists
EP4739706A1 (en) 2023-07-05 2026-05-13 CSL Innovation Pty Ltd Methods of treating or preventing a complication of sickle cell disease
WO2025008519A1 (en) 2023-07-05 2025-01-09 Universität Bern Il-1ra blockers for treatment and prevention of sepsis
CN122003247A (zh) 2023-07-07 2026-05-08 维里迪安治疗公司 治疗活动性和慢性甲状腺眼病的方法
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025021293A1 (en) 2023-07-25 2025-01-30 Universität Zürich Disruption of rbr1 expression in plant cells
CN121605481A (zh) 2023-08-10 2026-03-03 中外制药株式会社 信息处理系统、信息处理方法、程序和用于制造分子化合物的方法
WO2025061682A1 (en) 2023-09-21 2025-03-27 Universität Zürich Adenoviral targeting of dendritic cells
KR20260085122A (ko) 2023-09-29 2026-06-08 악티스 온콜로지, 인크. 미니단백질, 접합체 및 이의 용도
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
AU2024373680A1 (en) 2023-11-03 2026-06-18 Neuvasq Biotechnologies Sa Wnt7 signaling agonists
AU2024408268A1 (en) 2023-12-17 2026-07-09 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025137687A2 (en) * 2023-12-22 2025-06-26 Conagen Inc. Production of peptides using tandem repetitive recombination strategy
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
CN122438868A (zh) 2024-01-05 2026-07-21 分子合作伙伴股份公司 多特异性结合蛋白
WO2025151502A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Modified antibodies
WO2025151496A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151492A1 (en) 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025149633A1 (en) 2024-01-12 2025-07-17 Laigo Bio B.V. Bispecific antigen binding proteins
AU2025207813A1 (en) 2024-01-12 2026-07-23 Novelty Nobility Inc. Bispecific antibody specifically binding to c-kit and vegf, and use thereof
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2025191133A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Il-21 muteins, fusion proteins comprising the same and uses thereof
WO2025191136A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Muteins of 4-1bb ligand extracellular domain, fusion proteins comprising the same and uses thereof
WO2025191139A1 (en) 2024-03-15 2025-09-18 Avidicure Ip B.V. Conjugates of her2-specific antigen binding proteins and cytokines
WO2025202503A1 (en) 2024-03-28 2025-10-02 Universität Zürich Extracellular vesicles carrying cancer specific splice variants
WO2025222129A2 (en) 2024-04-19 2025-10-23 Mozart Therapeutics, Inc. Engineered cytokines and targeted cytokine delivery
TW202613158A (zh) 2024-05-16 2026-04-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2026013218A1 (en) 2024-07-10 2026-01-15 Ac Immune Sa Anti-tdp-43 vectors, binding molecules and uses thereof
WO2026013280A1 (en) 2024-07-11 2026-01-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Designed ankyrin repeat proteins binding p53, and uses thereof
US20260015407A1 (en) 2024-07-15 2026-01-15 Flagship Pioneering Innovations Vii, Llc Immunomodulatory fusion proteins and related methods
WO2026052650A1 (en) 2024-09-05 2026-03-12 F. Hoffmann-La Roche Ag Use of fap-cd40 bispecific antibody for the modulation of the tumor microenvironment
EP4729541A1 (en) 2024-10-16 2026-04-22 Paolo Fiorina Anti- igfbp7 antibodies and uses thereof
WO2026087748A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for the expansion of γδ t cells and use thereof
WO2026087747A1 (en) 2024-10-24 2026-04-30 Avidicure Ip B.V. Multispecific antigen binding proteins for tumor-targeting of γδ1 t cells and use thereof
WO2026093923A1 (en) 2024-10-29 2026-05-07 Csl Behring Ag Method for detection of a plasma protein
WO2026093563A2 (en) 2024-10-31 2026-05-07 Molecular Partners Ag Multispecific binding proteins and their use
GB202417141D0 (en) 2024-11-21 2025-01-08 Cambridge Entpr Ltd In vitro screening system
WO2026122747A2 (en) 2024-12-05 2026-06-11 Flagship Pioneering Innovations Vii, Llc Novel immunomodulatory proteins and related methods
WO2026150109A1 (en) 2025-01-10 2026-07-16 Molecular Partners Ag Mesothelin-specific binding constructs and their use in radiotherapy

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU612340B2 (en) * 1986-11-04 1991-07-11 Protein Polymers Technologies, Inc. Construction of synthetic dna and its use in large polypeptide synthesis
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
EP0903408A3 (en) 1992-08-21 2005-11-02 Biogen, Inc. Tat-derived transport polypeptide
CA2196419C (en) * 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
DE19631106A1 (de) 1996-08-01 1998-02-05 Heinz Peter Brandstetter Statorplatte oder Statorelement
US5932440A (en) * 1996-08-16 1999-08-03 Life Technologies, Inc. Mammalian ribonuclease inhibitors and use thereof
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
US5827692A (en) * 1997-04-24 1998-10-27 Heska Corporation Dirofilaria and Brugia ankyrin proteins, nucleic acid molecules, and uses thereof
EP1009422A4 (en) * 1997-07-18 2003-03-19 Univ Yale STRUCTURE OF THE ANKYRINE BONDING POINT OF AN ALPHA-NA, K-ATPASE
CA2350417C (en) 1998-12-02 2010-02-09 Bristol-Myers Squibb Company Dna-protein fusions and uses thereof
DE69941267D1 (de) 1998-12-10 2009-09-24 Bristol Myers Squibb Co Proteingerüste für antikörper-nachahmer und andere bindende proteine
US20020042094A1 (en) * 1999-12-15 2002-04-11 Venezia Domenick R. RING finger protein zapop2
WO2001061005A2 (en) * 2000-02-17 2001-08-23 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
US20020035739A1 (en) 2000-05-05 2002-03-21 Michael Lassner Evolution of plant disease response plant pathways to enable the development of based biological sensors and to develop novel disease resistance strategies
AU2001278859A1 (en) * 2000-06-29 2002-01-14 University Of Florida Ubiquitin ligase

Also Published As

Publication number Publication date
ATE448301T1 (de) 2009-11-15
US20040132028A1 (en) 2004-07-08
US20120142611A1 (en) 2012-06-07
JP2013179942A (ja) 2013-09-12
US9657287B2 (en) 2017-05-23
WO2002020565A2 (en) 2002-03-14
EP1332209B1 (en) 2009-11-11
JP2004508033A (ja) 2004-03-18
US9006389B2 (en) 2015-04-14
US20150275201A1 (en) 2015-10-01
ES2335861T3 (es) 2010-04-06
JP5291279B2 (ja) 2013-09-18
AU2002218166A1 (en) 2002-03-22
US7417130B2 (en) 2008-08-26
EP2149604A1 (en) 2010-02-03
US20090082274A1 (en) 2009-03-26
CA2421447A1 (en) 2002-03-14
DE60140474D1 (de) 2009-12-24
EP1332209A2 (en) 2003-08-06
US8110653B2 (en) 2012-02-07
JP2016053031A (ja) 2016-04-14
WO2002020565A3 (en) 2002-11-07
CA2421447C (en) 2012-05-08

Similar Documents

Publication Publication Date Title
AU2002218166A1 (en) Collections of repeat proteins comprising repeat modules
DE60310731D1 (de) Neue, von noraporphin abgeleitete moleküle
ATE518932T1 (de) Pha-mischungen
DE60330842D1 (de) Für den nachweis von nukleinsäuren kompetente biologische rohderivate
DK1257648T3 (da) Antagonistiske selektive bindingsmidler af osteoprotegerin-bindingsprotein
ATE519741T1 (de) Racemattrennung von (1-benzyl-4-methylpiperidin-3-yl)-methylamin
CY1112101T1 (el) Νευροτροφικοι παραγοντες
NO20042159L (no) Cellokulturprosess
DE60230149D1 (de) Steuersystem zur rückgewinnung von helium
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
SE9803838D0 (sv) A chromatography method and a column material useful in said method
DE60112276D1 (de) Elektrophoretische trennung von verbindungen
ATE453648T1 (de) Verfahren zur herstellung von hexahydrofuroc2,3- büfuran-3-ol
EP1692255A4 (en) EXTRACTION OF NUCLEIC ACID FROM EPITHELIAL CELLS FROM THE MOUTH
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
DE60201084D1 (de) Herstellung von cyclischen esteroligomeren
DK1680430T3 (da) Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat
NO20040877L (no) Cyklisk aminforbindelse.
ATE506351T1 (de) Verfahren zur herstellung von 10,11-dihydro-10- oxo-5h-dibenzoäb,füazepin-5-carboxamid
DK1366195T3 (da) Fremgangsmåde til detektion af nukleinsyremolekyler
EP1695069A4 (en) HYDROGEN SULFIDE MONITORING SYSTEM
NO20041763L (no) Regulert nukleinsyreekspresjonssystem
DE60210778D1 (de) Verfahren zur herstellung von 4-amino-2,5-bisheterocyclylchinazolinen
DK1005532T3 (da) Isolerede nukleinsyremolekyler kodende for SSX familiemedlemmer og anvendelser deraf
DK1383796T3 (da) Neurovirulent stamme af viruset West Nile og anvendelser heraf